ATS acquires BioDot Inc.
- April 21, 2021
According to ATS, the $106 million (US$84 million) is expected to close in the second quarter of 2021. ATS plans to fund the acquisition by drawing on its revolving credit facility.
“The addition of BioDot expands our Life Sciences capabilities in precise, low volume fluid dispensing and enhances our position in the point-of-care and clinical diagnostics lab automation end-markets,” said Andrew Hider, CEO of ATS. “With a long track record, applications expertise and deep customer relationships, BioDot’s systems enable customers to manufacture billions of test devices annually. Given the transition toward near-patient and at-home diagnostic testing for a broad range of infectious diseases including Covid-19, and other medical and non-medical testing applications, the acquisition of BioDot will allow us to play a bigger role in supporting the needs of our Life Sciences customers for the long term.”
BioDot manufactures non-contact and quantitative fluid dispensing systems that meet stringent industry requirements and address customer needs in R&D, pilot production and rapid, high-volume production. BioDot has 94 employees spread across its two US manufacturing facilities and locations in China and the UK.
“By leveraging the combined technologies and capabilities of BioDot and ATS, we will create unique solutions for our global customer base. Joining ATS will also allow us to ramp up our R&D efforts and will provide new opportunities for our talented employees. We look forward to the next chapter of BioDot’s growth within ATS,” says CEO Tony Lemmo, who will continue to be lead BioDot after the acquisition closes.